Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (DE:4AB)
XETRA:4AB
AbbVie (4AB) Stock Price & Analysis
10 Followers
4AB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€115.42 - €167.35
Previous Close€150.98
Volume1.00
Average Volume (3M)720.00
Market Cap
€264.08B
Enterprise Value€307.60B
Total Cash (Recent Filing)$12.82B
Total Debt (Recent Filing)$59.38B
Price to Earnings (P/E)60.0
Beta<0.01
Next Earnings
Jul 26, 2024EPS Estimate
€2.71Last Dividend Ex-Date
Apr 12, 2024Dividend Yield3.58%
Share Statistics
EPS (TTM)2.51
Shares Outstanding1,766,473,359
10 Day Avg. Volume828
30 Day Avg. Volume720
Standard Deviation0.07
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-3.64
Price to Sales (P/S)4.91
Price to Cash Flow (P/CF)14.80
P/FCF Ratio14.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.66
Enterprise Value/Gross Profit9.07
Enterprise Value/Ebitda19.20
Forecast
1Y Price Target
€167.32Price Target Upside7.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
AbbVie News
Bulls Say, Bears Say
Bulls Say
Market ExpansionAlvotech announced a long-term agreement to enhance access to Adalimumab-ryvk in the U.S. market.
Product Approval & Market Fit'951 has been approved in the EU and Japan, supporting positive outcomes for upcoming PDUFA.
Strategic AcquisitionAbbVie's acquisition of Landos at a significant premium reflects a strong belief in the strategic value and growth potential Landos brings to the company.
Bears Say
Competition ImpactHeme-onc sales could slightly miss due to competition, with Imbruvica and Venclexta demand softer year over year.
Earnings ForecastTotal Revenue for 1Q24 is projected to show a 2% decrease according to the latest consensus estimates.
Product PerformanceSandoz’s biosimilar Humira, Hyrimoz, has stepped up dramatically in recent weeks, driven by CVS’s hard switch for part of its patient base.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.27% Insiders
21.66% Mutual Funds
21.92% Other Institutional Investors
56.16% Public Companies and
Individual Investors
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €115.42 and its highest was €167.35 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Jul 26, 2024 which is in 84 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Apr 26, 2024. The company reported €2.157 earnings per share for the quarter, beating the consensus estimate of €2.111 by €0.047.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of €1.45 which represents an annual dividend yield of 3.58%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is €2.71.
How many shares outstanding does AbbVie have?
AbbVie has 1,770,647,000 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €2.157 in its last earnings report, beating expectations of €2.111. Following the earnings report the stock price went down -3.019%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 208M.
---
AbbVie Stock Smart Score
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
4AB Earnings Call
Q1 2024
0:00 / 0:00
---
4AB Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
4AB Stock 12 Months Forecast
Average Price Target
€167.32
▲(7.78% Upside)
Technical Analysis
Best Analysts Covering 4AB
1 Year
1 Year Success Rate
20/23 ratings generated profit
1 Year Average Return
+16.47%
reiterated a buy rating 5 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +16.47% per trade.
---